- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| NKGEN BIOTECH Aktie jetzt für 0€ handeln | |||||
| Di | NKGen Biotech, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 09.04. | NKGen Biotech, Inc.: NKGen Biotech to Present Troculeucel Mechanism Data in Alzheimer's and Frontotemporal Dementia at the Neuroimmunology Drug Development Summit | 2 | GlobeNewswire (USA) | ||
| 23.03. | NKGen reports cognitive stability in moderate Alzheimer's trial | 3 | Investing.com | ||
| 23.03. | NKGen meldet kognitive Stabilität in Alzheimer-Studie - Aktie steigt um 150 % | 1 | Investing.com Deutsch | ||
| 23.03. | NKGen Biotech, Inc.: NKGen Biotech Reports Combined Phase 1 Troculeucel Data Demonstrating Dose-Responsive Cognitive Improvements and Biomarker Correlations in Alzheimer's Disease at AD/PD 2026 | 145 | GlobeNewswire (Europe) | Pooled analyses in patients with moderate Alzheimer's show dose-related cognitive benefit and signs of durability. 100% of patients remained stable or improved, with 50% improving from moderate to... ► Artikel lesen | |
| 10.03. | NKGen to present Alzheimer's therapy data at AD/PD conference | 1 | Investing.com | ||
| 10.03. | NKGen Biotech, Inc.: NKGen Biotech to Present Integrated Phase 1 Clinical and Biomarker Analyses for Troculeucel in Alzheimer's Disease at AD/PD 2026 | 3 | GlobeNewswire (USA) | ||
| 26.02. | NKGen Biotech, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 05.02. | NKGen Biotech, Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| 26.01. | NKGen Biotech, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 22.01. | NKGen Biotech appoints neurology expert Dr. Bruce Miller to advisory board | 1 | Investing.com | ||
| 22.01. | NKGen Biotech, Inc.: NKGen Biotech Names Leading Dementia Expert Bruce L. Miller, M.D. to Scientific Advisory Board | 159 | GlobeNewswire (Europe) | SANTA ANA, Calif., Jan. 22, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization... ► Artikel lesen | |
| 20.01. | NKGen Biotech, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 16.01. | Nkgen Biotech sichert sich weitere 295.000 US-Dollar durch Darlehensanpassung | - | Investing.com Deutsch | ||
| 16.01. | NKGen Biotech, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 09.01. | NKGen Biotech, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 03.12.25 | NKGen Biotech, Inc. Issues Statement on Recent Board Appointments at Majority-Owned Korean Affiliate NKGen Korea Co., Ltd. | 9 | GlobeNewswire (USA) | ||
| 09.09.25 | NKGen Biotech, Inc. Announces Completion of NKMax Co., Ltd. Acquisition; Gains Full Control of Global Manufacturing and Intellectual Property Assets | 369 | GlobeNewswire (Europe) | NKGen acquires controlling stake in NKMax, marking a pivotal moment in its transformation into a fully integrated, self-sustaining, cell therapy company with global manufacturing and IP control.Approximately... ► Artikel lesen | |
| 16.07.25 | NKGen Biotech, Inc.: NKGen Biotech Announces New Funding to Regain Compliance with Reporting Obligations and Listing Standards | 264 | GlobeNewswire (Europe) | Funding in the amount of $2.0M from Japanese strategic investor, in the form of common equity PIPE with warrants. New funding provides for necessary resources to regain compliance with reporting... ► Artikel lesen | |
| 10.07.25 | NKGen Biotech, Inc.: NKGen Biotech Administers First Dose of Troculeucel to Alzheimer's Patient Who Continued to Decline Cognitively While on Prior Amyloid-Targeting Therapy | 240 | GlobeNewswire (Europe) | SANTA ANA, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization... ► Artikel lesen |
1 2 Weiter >>
22 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ARCELLX | 115,03 | -0,01 % | Arcellx, Inc. - 10-K/A, Annual Report | ||
| SUMMIT THERAPEUTICS | 22,080 | -0,81 % | Stifel reiterates Summit Therapeutics stock rating on trial data | ||
| QIAGEN | 32,580 | +0,12 % | Aktien New York Ausblick: Moderate Gewinne - Lage in Nahost sorgt für Vorsicht | NEW YORK (dpa-AFX) - Am US-Aktienmarkt werden am Dienstag zum Handelsstart moderate Gewinne erwartet. Angesichts der unsicheren Lage in Nahost dominiert - wie bereits zum Wochenstart - die Vorsicht.... ► Artikel lesen | |
| ERASCA | 21,490 | -4,40 % | Erasca, Inc. - 8-K, Current Report | ||
| ADMA BIOLOGICS | 11,260 | +1,67 % | ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today? | ||
| BEAM THERAPEUTICS | 27,105 | -10,13 % | Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up... ► Artikel lesen | |
| RELAY THERAPEUTICS | 15,130 | +0,33 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Data from Zovegalisib + Fulvestrant at the Phase 3 Dose of 400mg BID Fed at ESMO Targeted Anticancer Therapies Congress 2026 | 400mg BID fed is the dose used in the ongoing Phase 3 ReDiscover-2 trial, which initiated mid-2025 11.1-month median PFS in heavily pre-treated patients with PI3Ka-mutated, HR+/HER2- metastatic breast... ► Artikel lesen | |
| TANGO THERAPEUTICS | 25,760 | -0,43 % | Stifel reiterates Tango Therapeutics stock rating on combo potential | ||
| ENVERIC BIOSCIENCES | 5,020 | +24,57 % | What's Going On With Enveric Biosciences Stock On Friday? | ||
| EVOTEC | 5,350 | -0,93 % | Insiderverkäufe, Kaufempfehlungen und KI-Fantasie: BioNTech, Evotec, Vidac Pharma Aktie. | Insiderverkäufe bei Vidac Pharma. Dies ist jedoch kein Alarmsignal, sondern bietet eher eine Einstiegschance. Das Unternehmen arbeitet an einer revolutionären Krebstherapie. In 2026 sollen wichtige... ► Artikel lesen | |
| VERA THERAPEUTICS | 37,700 | -1,80 % | Vera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer | BRISBANE, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients... ► Artikel lesen | |
| NUVALENT | 104,53 | -3,28 % | Nuvalent präsentiert AACR-Daten vor PDUFA-Entscheid im September | ||
| BIONTECH | 90,15 | +0,22 % | Biontech im freien Fall: Droht jetzt der nächste große Absturz? - Positionieren Sie sich vor Börseneröffnung | ||
| FIRST TRACKS BIOTHERAPEUTICS | 18,160 | -4,47 % | AnaptysBio, Inc.: Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial Collaborations | Focused on protecting and returning value of Jemperli and imsidolimab royalties to shareholdersLaunches with virtual model, including limited FTEs and minimal operating expenses, and approximately... ► Artikel lesen | |
| MAPLIGHT THERAPEUTICS | 29,760 | +2,62 % | MapLight Therapeutics, Inc.: MapLight Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | Phase 2 ZEPHYR trial of ML-007C-MA for schizophrenia expected to reach target enrollment (n=300) in April 2026, with topline results expected in the third quarter of 2026Phase 2 IRIS trial for ML-004... ► Artikel lesen |
Das Unternehmen NKGEN BIOTECH INC kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NKGEN BIOTECH INC finden Sie auf Wallstreet Online.